Jade Biosciences to Participate in Upcoming Conferences
Rhea-AI Summary
Jade Biosciences (Nasdaq: JBIO) will participate in multiple investor conferences in late February and March 2026, including Oppenheimer, TD Cowen, Leerink, and Jefferies.
Management will present, host fireside chats, and hold one-on-one investor meetings. According to the company, live webcasts will be available on the Events & Presentations page with replays archived for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, JBIO gained 3.79%, reflecting a moderate positive market reaction. Argus tracked a peak move of +4.1% during that session. This price movement added approximately $26M to the company's valuation, bringing the market cap to $708M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
JBIO was up 0.28% with flat/ mixed peers: IVVD showed notable strength, while ALLO was flat and RAPT/RNAC slightly down. Only 1 peer (IVVD) appeared in momentum scans, supporting a stock-specific tone to this conference news.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 05 | Pipeline objectives | Positive | -7.3% | Outlined 2026 pipeline milestones and cash runway into first half 2028. |
| Dec 15 | Private placement | Positive | +1.8% | Announced $45M private placement to support R&D and corporate needs. |
| Nov 13 | Earnings and update | Positive | -3.2% | Reported Q3 results, clinical advances and major financing strengthening liquidity. |
| Nov 03 | Conference participation | Neutral | -3.4% | Planned participation in multiple November 2025 investor and healthcare conferences. |
| Oct 17 | Clinical data update | Positive | +6.7% | Announced new preclinical and translational data for JADE101 at ASN Kidney Week. |
JBIO has shown mixed reactions to news: conference participation has coincided with modest declines, while clinical/data news has sometimes produced stronger upside. Financing-related headlines have seen both positive and negative next-day moves.
Over the past few months, JBIO has combined active pipeline updates with multiple financing and conference announcements. A Nov 2025 data presentation for JADE101 saw a 6.72% gain, while a detailed Jan 5, 2026 objectives and cash runway update was followed by a 7.34% decline. Private placement and earnings-related headlines in Nov–Dec 2025 produced smaller, mixed moves. Today’s conference-participation news fits a pattern of ongoing investor-engagement efforts alongside clinical progress and capital-raising steps.
Market Pulse Summary
This announcement highlights JBIO’s participation in several healthcare investor conferences between February 25 and March 11, 2026, with webcast access for 90 days. These events provide venues for management to update investors on clinical and strategic progress. Historically, conference news alone has had modest impact compared with data and financing updates, so attention may remain on future trial readouts, capital allocation, and any subsequent regulatory or corporate filings.
AI-generated analysis. Not financial advice.
SAN FRANCISCO and VANCOUVER, British Columbia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences:
- Oppenheimer 36th Annual Healthcare Life Sciences Conference | February 25-26, 2026
Presentation: Thursday, February 26 at 1:20 p.m. ET |Track 3 - TD Cowen 46th Annual Health Care Conference | March 2-4, 2026
Presentation & Fireside Chat: Monday, March 2 at 10:30 a.m. ET - Leerink Global Healthcare Conference | March 8-11, 2026
Fireside Chat: Wednesday, March 11 at 8:40 a.m. ET - Jefferies Biotech on the Beach Summit | March 10-11, 2026
Members of the Jade management team will host one-on-one investor meetings during the conferences.
A live webcast of the presentations will be available on the Events & Presentations page of the Jade Biosciences website, with an archived replay accessible for 90 days following the event.
About Jade Biosciences, Inc.
Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade’s lead candidate, JADE101, targets the cytokine APRIL, and is currently being evaluated in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. Jade’s pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, as well as JADE301, an undisclosed antibody program, both currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit JadeBiosciences.com and follow the Company on LinkedIn.
Forward-Looking Statements
Certain statements in this communication, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Jade’s expectations, hopes, beliefs, intentions or strategies regarding the future of its pipeline and business including, without limitation, the potential of Jade’s product candidates to become best-in-class therapies and their potential therapeutic uses. The words “opportunity,” “potential,” “milestones,” “pipeline,” “can,” “goal,” “strategy,” “target,” “anticipate,” “achieve,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “possible,” “project,” “should,” “will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Jade will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Jade’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that adverse events or safety signals may occur; Jade may experience unanticipated costs, difficulties or delays in the product development process; Jade’s product candidates may fail in development or may not receive required regulatory approvals; and the other risks, uncertainties and factors more fully described in Jade’s most recent filings with the Securities and Exchange Commission (including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2025). Should one or more of these risks or uncertainties materialize, or should any of Jade’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Jade does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Jade.
Jade Biosciences Contact
Priyanka Shah
Media@JadeBiosciences.com
IR@JadeBiosciences.com
908-447-6134
FAQ
When will JBIO present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference?
What is the schedule for Jade Biosciences (JBIO) at the TD Cowen 46th Annual Health Care Conference?
How can investors watch JBIO presentations from the Leerink Global Healthcare Conference?
Will Jade Biosciences (JBIO) attend Jefferies Biotech on the Beach Summit and how will they engage investors?
Where can I find JBIO webcast replays and how long will they remain available?
